Key Takeaways:
Sonnet BioTherapeutics has announced a significant merger valued at $888 million, aiming to establish a public reserve for the HYPE token. The newly formed entity, Hyperliquid Strategies Inc (HSI), is set to become the largest U.S.-listed holder of HYPE. Major cryptocurrency investors, including Paradigm, Galaxy Digital, and Pantera Capital, are backing this ambitious initiative.
Sonnet’s Strategic Shift: From Oncology to On-Chain
In a groundbreaking move, Sonnet BioTherapeutics (NASDAQ: SONN), which previously concentrated on oncology, revealed on July 14 that it has entered into a definitive agreement with Rorschach I LLC—a crypto-centric organization formed by affiliates of Atlas Merchant Capital and Paradigm Operations LP. This agreement will lead to the establishment of Hyperliquid Strategies Inc. (HSI), a publicly traded company focused on managing a treasury of HYPE, the native token of the Hyperliquid Layer-1 blockchain. Under the deal’s terms, HSI will acquire 12.6 million HYPE tokens valued at approximately $583 million, along with an additional $305 million in cash, culminating in a total valuation of $888 million upon closing. HSI will continue to be traded on Nasdaq under a new ticker symbol, positioning itself as one of the largest public holders of HYPE globally, a bold move reminiscent of MicroStrategy’s shift towards Bitcoin.
Crypto Meets Wall Street: Major Backers Line Up
This transaction has garnered support from a formidable lineup of institutional investors, including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. These investors bring a wealth of experience in the cryptocurrency space, indicating robust confidence in both the Hyperliquid ecosystem and the future value of HYPE.
Hyperliquid’s Growing Influence in the Blockchain Sector
Hyperliquid is gaining recognition as a Layer-1 blockchain that excels in its high-throughput on-chain trading capabilities. It comprises two primary components: HyperCore, which facilitates on-chain perpetual futures and can handle up to 200,000 orders per second, and HyperEVM, a versatile smart contract platform that enhances HyperCore’s liquidity for decentralized applications (dApps) and developers. The network utilizes a unique consensus mechanism known as HyperBFT, which enhances its speed and scalability, providing a competitive edge over established blockchain networks. As of July 6, HYPE ranks as the 13th largest cryptocurrency by market capitalization, a status few anticipated. However, U.S. investors face challenges in accessing the token directly, creating an opportunity for HSI to offer indirect exposure through equity markets.
Leadership Reshuffle and Strategic Direction
Upon closing the merger, HSI will be guided by seasoned industry professionals: Bob Diamond, Co-founder and CEO of Atlas Merchant Capital, will take on the role of Chairman, while David Schamis from Atlas will assume the position of CEO. Eric Rosengren, the former President of the Boston Federal Reserve, will join the board alongside two independent directors from Sonnet. The leadership team aims to establish HSI as a pioneering model for crypto-centric treasury management in public markets. A Sponsor Advisory Agreement (SAA) will be created with Rorschach to incorporate HYPE into a long-term treasury strategy. This approach mirrors the strategy employed by MicroStrategy with Bitcoin but focuses on different tokens and infrastructure.
Why HYPE and Why Now?
Matt Huang, Co-founder of Paradigm, emphasized that Hyperliquid has emerged as a protocol with solid fundamentals, highlighting its high product quality, a rapidly expanding community, and technical capabilities that can compete with Ethereum. The scarcity of HYPE, combined with strong demand from U.S. investors, presents an appealing framework for HSI as a public equity proxy for tokens. As the cryptocurrency market enters a new cycle and institutional interest grows, the timing of this move is seen as strategic, influenced by factors such as potential spot ETF approvals and regulatory clarity following recent market developments.
Dual Business Model: Biotech Remains for Now
Interestingly, Sonnet’s existing biotech operations will persist under the HSI umbrella as a wholly owned subsidiary. The company plans to maintain its focus on its clinical pipeline, including the development of SON-1010, while divesting non-core assets. To facilitate this transition, Sonnet has secured $5.5 million through a private placement of convertible preferred shares and warrants, and $2 million in convertible notes will be converted at the transaction’s completion. A Contingent Value Right (CVR) will also be issued to shareholders, linked to the biotech assets. This structure allows investors to gain exposure to the crypto pivot while still benefiting from the potential upside of Sonnet’s ongoing oncology programs.
